BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005). (Q45436276)

14 December 2017

BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005). (English)

1 reference

14 December 2017

0 references

1 reference

M Nelson

1

1 reference

14 December 2017

G Matthews

2

1 reference

14 December 2017

M G Brook

3

1 reference

14 December 2017

J Main

4

1 reference

14 December 2017

BHIVA Coinfection Guideline Committee

5

1 reference

14 December 2017

British HIV Association

6

1 reference

14 December 2017

1 July 2005

1 reference

14 December 2017

1 reference

14 December 2017

6 Suppl 2

1 reference

14 December 2017

96-106

1 reference

Syphilis: old problem, new strategy

14 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Hepatitis C and progression of HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Liver toxicity caused by nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Use and interpretation of virological tests for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Pathologic features of chronic hepatitis. A review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

HCV chronic hepatitis in patients with HIV: clinical management issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Mitochondrial toxic effects and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Report of three cases of hyperlactacidemiae/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00300.X

10.1111/J.1468-1293.2005.00300.X

21 January 2018

Identifiers

DOI

1 reference

14 December 2017

1 reference